Attached files
| file | filename |
|---|---|
| S-1/A - AMENDMENT NO. 3 TO FORM S-1 - Oncotelic Therapeutics, Inc. | d579993ds1a.htm |
| EX-4.8 - EX-4.8 - Oncotelic Therapeutics, Inc. | d579993dex48.htm |
| EX-4.9 - EX-4.9 - Oncotelic Therapeutics, Inc. | d579993dex49.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the reference to our firm under the caption “Experts” in Amendment No. 3 to the Registration Statement (Form S-1 No. 333-190464) and related Prospectus of OXiGENE for the registration of up to 3,496,503 units, each consisting of one share of common stock and one half of a warrant, and to the incorporation by reference therein of our report dated March 15, 2013, with respect to the financial statements of OXiGENE, Inc., included in its Annual Report (Form 10-K) for the year ended December 31, 2012, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Redwood City, California
January 31, 2014